Clinical Trial Update: A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pharmacokinetics of a single IV 300 mg dose of vedolizumab in healthy adult Chinese participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Colitis, Ulcerative, Crohn Disease | Phase 1 | Status: COMPLETED | Results posted: 2019-09-06